Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 50,000,000
    Countries
    Sector(s)
    Germany : € 50,000,000
    Services : € 50,000,000
    Signature date(s)
    29/04/2020 : € 25,000,000
    29/04/2020 : € 25,000,000

    Summary sheet

    Release date
    24 April 2020
    Status
    Reference
    Signed | 29/04/2020
    20190880
    Project name
    Promoter - financial intermediary
    INNOVATIVE CELL THERAPIES (EGFF) (COVID-19)
    PLURISTEM GMBH
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 50 million
    EUR 100 million
    Location
    Sector(s)
    • Services - Professional, scientific and technical activities
    Description
    Objectives

    The promoter is a clinical-stage biotherapy company that use placental stem cells and its unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, haematological disorders and mucosal repair following a severe infection, as well as complications from COVID-19 infection.

    The proposed transaction will support R&D investments that are required in order to further advance the promoter's product pipeline and bring the products to market.

    Environmental aspects
    Procurement

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending 2011/92/EU. Full environmental details will be verified during the appraisal.

    The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Link to source

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - INNOVATIVE CELL THERAPIES (EGFF)
    Publication Date
    24 May 2020
    Document language
    Main Topic
    Lending
    Document Number
    127656520
    Document Focus
    Environmental Information
    Project Number
    20190880
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now
    Environmental and Social Completion Sheet (ESCS) - INNOVATIVE CELL THERAPIES (EGFF) (COVID-19)
    Publication Date
    1 Nov 2023
    Document language
    Main Topic
    Lending
    Document Number
    171875362
    Document Focus
    Environmental Information
    Project Number
    20190880
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now
    scoreboard - EUROPEAN GROWTH FINANCE FACILITY
    Publication Date
    13 Sep 2019
    Document Language
    English
    Main Topic
    lending
    Document Number
    122912044
    Document Focus
    EFSI legal requirements
    Document Type
    Scoreboard
    Project Number
    20180667
    Last update
    19 Aug 2020
    Sector(s)
    Services
    Countries
    Bulgaria, Kenya, Ghana, Mexico, Philippines
    Publicly available
    Download now

    News & Stories

    Videos

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications